Daiichi Sankyo has secured the US Food and Drug Administration (FDA) approval for its Turalio (pexidartinib) capsules to treat adult patients with symptomatic tenosynovial giant cell tumour (TGCT).
Date:2019-08-07 Views:528
Daiichi Sankyo has secured the US Food and Drug Administration (FDA) approval for its Turalio (pexidartinib) capsules to treat adult patients with symptomatic tenosynovial giant cell tumour (TGCT).
